Subcutaneous Biologics, Technologies and Drug Delivery Systems (2nd Edition), 2018-2030'"
With more than 90 Approved Products and over 240 Clinical Candidates, the Subcutaneous Biologics Market is Projected to Witness Commendable Growth across the Next Decade, Predicts Roots Analysis
Rupali Verma, the principal analyst, stated, "Close to 45% of the subcutaneously administrable biologics are monoclonal antibodies; these are followed by other types of protein-based therapeutics, including interferons, interleukins, hormones, enzymes and cytokines. Further, even certain vaccines, recombinant peptides and cell / gene therapies are other therapy types being evaluated for subcutaneous delivery. Moreover, ongoing technical advances have led to the development of innovative technology platforms designed to enable the delivery of highly viscous formulations as well."
The report presents opinions on several key aspects of the market. Among other elements, it includes:
1. A detailed assessment of the current market landscape of commercially available biologics that are designed for delivery via the subcutaneous route, along with information on the developer(s)
2. An in-depth analysis of the various subcutaneous biologics that are currently under clinical development, with information on the developer(s)
3. A review of various innovative technology platforms that are used for the formulation of drugs for subcutaneous delivery, highlighting their key features and providing information on their developers, mechanisms of action and advantages. The study also includes an insightful three-dimensional analysis of the technology platforms that are presently engaged in developing drug formulations for subcutaneous delivery, comparing them based on pipeline strength (in terms of marketed / under development drugs based on the technology), supplier power (in terms of year of establishment and size of employee base) of the developer and a number of collaborations established related to the technology.
4. A detailed benchmark analysis of technology providers that are based in North America and Europe, highlighting the advantage(s)
5. Elaborate profiles of key technology providers, featuring an overview of the companies, a review of their proprietary technologies, mechanisms of action, key advantages, list of product candidates developed using the technology, recent developments related to the technology (funding and collaborations)
6. In-depth review of the most advanced and popular subcutaneous drug delivery systems, focused on large volume wearable injectors, autoinjectors, pen injectors, needle free injectors, prefilled syringes, drug reconstitution systems and implants, providing information on their developer(s)
7. Large volume wearable injectors: Type of device (infusion pump and patch pump), type of dose delivered (continuous and bolus), volume of drug container / storage capacity (in mL), usability (disposable and reusable) and stage of development (commercialized and under development)
9. Pen injectors: Usability (disposable and reusable), volume of the drug container (in mL) and dosage type (fixed dose and variable dose).
10. Needle free injection systems: Type of technology (jet, spring and gas), usability (disposable and reusable) and drug volume delivered (in mL).
11. Prefilled syringes: Type of syringe (glass and plastic).
12. Drug reconstitution systems: Type of device (dual chambered systems and other novel systems), type of container (cartridge and others) and usability (disposable and reusable).
13. Implants: Type of material (silicone, titanium, polymers and others), target therapeutic indication, type of implant (biodegradable and non-biodegradable)
14. A comprehensive product competitiveness analysis of large volume wearable injectors and subcutaneous autoinjectors taking into consideration the supplier power (based on size of employee base) and product specifications.
A discussion on affiliated trends, key drivers and challenges, under a SWOT framework. The analysis features a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on the overall subcutaneous products market.
Verma further added, "Despite the various limitations associated with subcutaneous formulations, the field offers immense opportunities to pharmaceutical companies, device manufacturers and technology developers. Companies are also reformulating their intravenous drugs for subcutaneous administration for life cycle management and product differentiation purposes. The rising incidence of chronic clinical conditions (which are characterized by the need for frequent administration of medications)
The research covers detailed profiles and assesses product portfolios of the following companies:
2. Ajinomoto Althea
4. Ascendis Pharma
5. Avadel Pharmaceuticals
7. Halozyme Therapeutics
9. Xeris Pharmaceuticals
10. Serina Therapeutics
For additional details, please visit
or email firstname.lastname@example.org